Marcyto

Glatiramer Acetate, the active ingredient in Marcyto, is an immunomodulator presented as a sterile solution for subcutaneous use. It is indicated for the treatment of relapsing‑remitting multiple sclerosis in adult patients, helping to reduce relapse frequency and slow disease progression.

GNH USA supplies Marcyto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marcyto is an immunomodulatory disease‑modifying therapy used in the management of multiple sclerosis and related disease activity. - Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows accumulation of disability. - Clinically isolated syndrome: may delay conversion to clinically definite multiple sclerosis when initiated early. - Active disease with MRI activity: helps decrease the formation of new inflammatory lesions.

Adverse reactions may occur with subcutaneous administration of glatiramer acetate.

Common Side Effects: - Injection site pain or erythema - Immediate post‑injection reaction (flushing, chest tightness, shortness of breath) - Transient headache - Nausea or abdominal discomfort - Fatigue - Localized swelling or induration

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reaction - Severe systemic allergic reaction (angioedema) - Guillain‑Barré syndrome (very rare) - Persistent neurologic worsening not attributable to disease activity - Severe injection‑site infection - Cardiac arrhythmia associated with immediate post‑injection reaction

Patients and healthcare providers should be aware of specific safety considerations when using Marcyto. - Monitor for immediate post‑injection reactions and be prepared to manage respiratory symptoms. - Assess for signs of hypersensitivity; discontinue if severe allergic response occurs. - Evaluate cardiac history before initiation, especially in patients with prior arrhythmias. - Counsel patients on proper injection technique to minimize local reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Glatiramer acetate has a low potential for drug‑drug interactions, but certain agents may modify its safety profile.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy and increase infection risk. - Immunosuppressive biologics (e.g., anti‑CD20 antibodies): may amplify immunomodulatory effects and raise infection risk.

Moderate Interactions (Monitor Closely): - Interferon‑beta therapies: combined use may increase injection‑site reactions. - Anticoagulants: monitor for bleeding if injection technique causes hematoma. - Other disease‑modifying therapies: assess cumulative immunomodulation and infection risk.